Subscribe
dna-istock-518143098-ralwel--2
ralwel / iStockphoto.com
22 March 2018Europe

LSIPR Webinar: Greater scrutiny for late-filed EPO documents, says HGF

Late-filed documents will come under greater scrutiny in light of changes to the European Patent Office’s (EPO) opposition procedure.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSIPR webinar: BSKB dissects antibody patents
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.
Big Pharma
LSIPR webinar: HGF delves into personalised healthcare patents
13 September 2018   Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.
Big Pharma
LSIPR webinar: HGF on doctrine of equivalence evolution
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Big Pharma
LSIPR webinar: HGF on doctrine of equivalence evolution
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.
Big Pharma
LSIPR webinar: HGF delves into personalised healthcare patents
13 September 2018   Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.
Americas
LSIPR webinar: BSKB dissects antibody patents
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.

More on this story

Big Pharma
LSIPR webinar: HGF on doctrine of equivalence evolution
16 October 2018   The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK.
Big Pharma
LSIPR webinar: HGF delves into personalised healthcare patents
13 September 2018   Personalised healthcare is a rapidly developing field, not just because of medical advancements, but also because the criteria necessary to secure second medical use patents has similarly evolved over the years, an industry webinar heard.
Americas
LSIPR webinar: BSKB dissects antibody patents
1 February 2018   When it comes to patenting antibodies, “written description seems to be the big issue these days”, according to Gerald Murphy, IP partner at law firm Birch Stewart Kolasch Birch.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court